Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nutrients ; 10(11)2018 Nov 20.
Artigo em Inglês | MEDLINE | ID: mdl-30463394

RESUMO

Gestational diabetes mellitus (GDM) is associated with maternal diet, however, findings are inconsistent. The aims of the present study were to assess whether intakes of foods and beverages during pregnancy differed between women who developed GDM and non-GDM women, and to compare dietary intakes with dietary recommendations of pregnancy. This is a nested case-control study within a randomized controlled trial. Women with complete measurements of a 75 g oral glucose tolerance test (OGTT) at 18⁻22 and 32⁻36 weeks gestation were included in the cohort (n = 702). Women were diagnosed for GDM according to the simplified International Association of Diabetes and Pregnancy Study Group criteria at 32⁻36 weeks (GDM women: n = 40; non-GDM women: n = 662). Dietary data (food frequency questionnaire) was collected at both time points and compared between GDM and non-GDM women. Variability in OGTT values was assessed in a general linear model. Marginal differences between GDM and non-GDM women in intakes of food groups were found. No associations were found between dietary variables and OGTT values. Not all dietary recommendations were followed in the cohort, with frequently reported alcohol consumption giving largest cause for concern. This study did not find dietary differences that could help explain why 40 women developed GDM.


Assuntos
Diabetes Gestacional/epidemiologia , Dieta , Adulto , Bebidas , Glicemia/análise , Índice de Massa Corporal , Registros de Dieta , Ingestão de Energia , Exercício Físico , Feminino , Alimentos , Idade Gestacional , Teste de Tolerância a Glucose , Humanos , Estudos Longitudinais , Fenômenos Fisiológicos da Nutrição Materna , Noruega/epidemiologia , Política Nutricional , Gravidez , Aumento de Peso
2.
J Am Heart Assoc ; 4(10): e002258, 2015 Oct 02.
Artigo em Inglês | MEDLINE | ID: mdl-26432801

RESUMO

BACKGROUND: Android fat distribution (abdominal obesity) is associated with insulin resistance, hepatic steatosis, and greater secretion of large very low-density lipoprotein (VLDL) particles in men. Since abdominal obesity is becoming increasingly prevalent in women, we aimed to investigate the relationship between android fat and hepatic lipid metabolism in pre- and postmenopausal women. METHODS AND RESULTS: We used a combination of stable isotope tracer techniques to investigate intrahepatic fatty acid synthesis and partitioning in 29 lean and 29 abdominally obese women (android fat/total fat 0.065 [0.02 to 0.08] and 0.095 [0.08 to 0.11], respectively). Thirty women were premenopausal aged 35 to 45 and they were matched for abdominal obesity with 28 postmenopausal women aged 55 to 65. As anticipated, abdominal obese women were more insulin resistant with enhanced hepatic secretion of large (404±30 versus 268±26 mg/kg lean mass, P<0.001) but not small VLDL (160±11 versus 142±13). However, postmenopausal status had a pronounced effect on the characteristics of small VLDL particles, which were considerably triglyceride-enriched (production ratio of VLDL2- triglyceride:apolipoprotein B 30±5.3 versus 19±1.6, P<0.05). In contrast to postmenopausal women, there was a tight control of hepatic fatty acid metabolism and triglyceride production in premenopausal women, whereby oxidation (rs=-0.49, P=0.006), de novo lipogenesis (rs=0.55, P=0.003), and desaturation (rs=0.48, P=0.012) were closely correlated with abdominal obesity-driven large VLDL-triglyceride secretion rate. CONCLUSIONS: In women, abdominal obesity is a major driver of hepatic large VLDL particle secretion, whereas postmenopausal status was characterized by increased small VLDL particle size. These data provide a mechanistic basis for the hyperlipidemia observed in postmenopausal obesity.


Assuntos
Hiperlipidemias/metabolismo , Metabolismo dos Lipídeos , Fígado/metabolismo , Obesidade Abdominal/metabolismo , Pós-Menopausa/metabolismo , Pré-Menopausa/metabolismo , Adiposidade , Adulto , Idoso , Apolipoproteína B-100/sangue , Apolipoproteína C-III/sangue , Ácidos Graxos/sangue , Feminino , Humanos , Hiperlipidemias/diagnóstico , Hiperlipidemias/fisiopatologia , Cinética , Lipogênese , Lipoproteínas VLDL/sangue , Pessoa de Meia-Idade , Obesidade Abdominal/diagnóstico , Obesidade Abdominal/fisiopatologia , Oxirredução , Tamanho da Partícula , Triglicerídeos/sangue , Aumento de Peso
3.
Obes Surg ; 21(6): 751-8, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21484524

RESUMO

BACKGROUND: Appetite-regulating hormones seem to play an important role in weight loss after bariatric surgery. Less is known regarding long-term weight loss maintenance. The objective of the study was to evaluate ghrelin and obestatin levels following long-term weight loss achieved through bariatric surgery or a lifestyle intervention in morbidly obese patients. METHODS: The study was cross-sectional in design carried out in a university research center setting. The participants were weight-stable morbidly obese patients who had undergone, on average, 3 years ago, Roux-en-Y gastric bypass (RYGB) surgery (n=9) or a lifestyle weight loss intervention (n=8), and patients on a waiting list for bariatric surgery (control group; n=9). The main outcome measures were fasting/postprandial plasma levels of total ghrelin and obestatin and ghrelin/obestatin ratio. RESULTS: Fasting ghrelin and obestatin plasma levels were significantly elevated in the RYGB, but not in the lifestyle group, as compared with the control group. There was no statistical significant difference in fasting ghrelin/obestatin ratio among study groups. Ghrelin levels were suppressed after breakfast in all groups, with no significant differences in postprandial levels overtime between them. Obestatin levels did not change postprandially in any of the groups, but the area under the curve was significantly higher in the RYGB than in the control group. CONCLUSIONS: Sustained weight loss maintenance seems to be associated with increased fasting levels of ghrelin and obestatin after RYGB surgery, but not after a lifestyle intervention, while maintaining ghrelin/obestatin ratio. Ghrelin is, therefore, unlikely to contribute to weight loss maintenance after RYGB, and other mechanisms are probably involved.


Assuntos
Derivação Gástrica , Grelina/sangue , Estilo de Vida , Obesidade Mórbida/sangue , Redução de Peso/fisiologia , Adulto , Estudos Transversais , Humanos , Pessoa de Meia-Idade , Obesidade Mórbida/terapia
4.
Metabolism ; 58(12): 1753-61, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19716144

RESUMO

Fatty acids (FA) can impair glucose metabolism to a varying degree depending on time of exposure and also of type of FA. Here we tested for acute effects of marine n-3 FA on insulin sensitivity, insulin secretion, energy metabolism, and oxidative stress. This was a randomized, double-blind, crossover study in 11 subjects with type 2 diabetes mellitus. A 4-hour lipid infusion (Intralipid [Fresenius Kabi, Halden, Norway], total of 384 mL) was compared with a similar lipid infusion partly replaced by Omegaven (Fresenius Kabi) that contributed a median of 0.1 g fish oil per kilogram body weight, amounting to 0.04 g/kg of marine n-3 FA. Insulin sensitivity was assessed by isoglycemic hyperinsulinemic clamps; insulin secretion (measured after the clamps), by C-peptide glucagon tests; and energy metabolism, by indirect calorimetry. Infusion of Omegaven increased the proportion of n-3 FA in plasma nonesterified fatty acids (NEFA) compared with Intralipid alone (20:5n-3: median, 1.5% [interquartile range, 0.6%] vs -0.2% [0.2%], P = .001; 22:6n-3: 0.8% [0.4%] vs -0.7% [0.2%], P = .001). However, glucose utilization was not affected; neither was insulin secretion or total energy production (P = .966, .210, and .423, respectively, for the differences between the lipid clamps). Omegaven tended to lower oxidation of fat (P = .062) compared with Intralipid only, correlating with the rise in individual n-3 NEFA (r = 0.627, P = .039). The effects of clamping on phospholipid FA composition, leptin, adiponectin, or F(2)-isoprostane concentrations were not affected by Omegaven. Enrichment of NEFA with n-3 FA during a 4-hour infusion of Intralipid failed to affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus.


Assuntos
Diabetes Mellitus Tipo 2/metabolismo , Emulsões Gordurosas Intravenosas/farmacologia , Ácidos Graxos Ômega-3/farmacologia , Resistência à Insulina/fisiologia , Insulina/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Adulto , Idoso , Biomarcadores , Composição Corporal/efeitos dos fármacos , Peptídeo C , Calorimetria Indireta , Estudos Cross-Over , Diabetes Mellitus Tipo 2/fisiopatologia , Dieta , Dinoprosta/metabolismo , Método Duplo-Cego , Emulsões Gordurosas Intravenosas/administração & dosagem , Ácidos Graxos não Esterificados/sangue , Feminino , Glucagon/metabolismo , Técnica Clamp de Glucose , Humanos , Infusões Intravenosas , Isoprostanos/metabolismo , Masculino , Pessoa de Meia-Idade
5.
Am J Clin Nutr ; 84(3): 540-50, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16960167

RESUMO

BACKGROUND: Effects of fish oil supplements on metabolic variables are insufficiently clarified in type 2 diabetes. OBJECTIVE: We aimed to investigate short-term (1 wk) and longer-term (9 wk) effects of n-3 fatty acids. DESIGN: Twenty-six subjects with type 2 diabetes without hypertriacylglycerolemia participated in a double-blind controlled study. Median intake in the intervention group was 17.6 mL fish oil/d (1.8 g 20:5n-3, 3.0 g 22:6n-3, and 5.9 g total n-3 fatty acids). The control group received 17.8 mL corn oil/d (8.5 g 18:2n-6). RESULTS: Plasma phospholipid 20:5n-3 and 22:6n-3 increased, whereas 18:2n-6 decreased, in the fish oil group compared with the corn oil group after 1 wk. The two n-3 fatty acids also increased in adipose tissue biopsy samples taken after 9 wk in the fish oil group. Glucose concentrations (home-monitored) were approximately 1 mmol/L higher in the fish oil group than in the corn oil group at the end of the intervention (P = 0.035). Glucose utilization measured by using an isoglycemic clamp was lowered in the fish oil group compared with that in the corn oil group at the end of the intervention (P = 0.049), whereas glucagon-stimulated C-peptide tended to increase (P = 0.078). The fish oil group utilized less fat for oxidation after 1 wk, with a change to more fat and less carbohydrate oxidation after 9 wk (P = 0.040), than did the corn oil group. CONCLUSION: A high intake of fish oil moderately increases blood glucose and decreases insulin sensitivity in persons with type 2 diabetes without hypertriacylglycerolemia and alters carbohydrate and fat utilization in a time-dependent manner.


Assuntos
Glicemia/efeitos dos fármacos , Metabolismo dos Carboidratos/fisiologia , Diabetes Mellitus Tipo 2/metabolismo , Gorduras Insaturadas na Dieta/metabolismo , Ácidos Graxos Ômega-3/administração & dosagem , Resistência à Insulina , Adulto , Idoso , Glicemia/metabolismo , Metabolismo dos Carboidratos/efeitos dos fármacos , Diabetes Mellitus Tipo 2/tratamento farmacológico , Suplementos Nutricionais , Método Duplo-Cego , Feminino , Óleos de Peixe , Técnica Clamp de Glucose , Hemostasia/efeitos dos fármacos , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Oxirredução , Consumo de Oxigênio , Fosfolipídeos/sangue , Fatores de Tempo
6.
Am J Physiol Endocrinol Metab ; 284(1): E129-37, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12485810

RESUMO

We tested the effects of acute perturbations of elevated fatty acids (FA) on insulin secretion in type 2 diabetes. Twenty-one type 2 diabetes subjects with hypertriglyceridemia (triacylglycerol >2.2 mmol/l) and 10 age-matched nondiabetic subjects participated. Glucose-stimulated insulin secretion was monitored during hyperglycemic clamps for 120 min. An infusion of Intralipid and heparin was added during minutes 60-120. In one of two tests, the subjects ingested 250 mg of Acipimox 60 min before the hyperglycemic clamp. A third test (also with Acipimox) was performed in 17 of the diabetic subjects after 3 days of a low-fat diet. Acipimox lowered FA levels and enhanced insulin sensitivity in nondiabetic and diabetic subjects alike. Acipimox administration failed to affect insulin secretion rates in nondiabetic subjects and in the group of diabetic subjects as a whole. However, in the diabetic subjects, Acipimox increased integrated insulin secretion rates during minutes 60-120 in the 50% having the lowest levels of hemoglobin A(1c) (379 +/- 34 vs. 326 +/- 30 pmol x kg(-1) x min(-1) without Acipimox, P < 0.05). A 3-day dietary intervention diminished energy from fat from 39 to 23% without affecting FA levels and without improving the insulin response during clamps. Elevated FA levels may tonically inhibit stimulated insulin secretion in a subset of type 2 diabetic subjects.


Assuntos
Diabetes Mellitus Tipo 2/fisiopatologia , Ácidos Graxos/sangue , Insulina/metabolismo , Adulto , Idoso , Glicemia/análise , Peptídeo C/sangue , Diabetes Mellitus/fisiopatologia , Diabetes Mellitus Tipo 2/complicações , Dieta com Restrição de Gorduras , Proteínas Alimentares/administração & dosagem , Ingestão de Energia , Exercício Físico , Jejum , Feminino , Glucagon/sangue , Técnica Clamp de Glucose , Hemoglobinas Glicadas/análise , Humanos , Hiperglicemia , Hipertrigliceridemia/complicações , Hipertrigliceridemia/fisiopatologia , Insulina/sangue , Secreção de Insulina , Masculino , Pessoa de Meia-Idade , Obesidade , Proinsulina/sangue , Pirazinas/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...